Anxiety disorders

Anxiety disorders
Name	Anxiety disorders
Field	Psychiatry, Clinical psychology
Symptoms	Excessive fear, worry, avoidance
Complications	Substance use disorder, depression, impaired functioning
Onset	Childhood, adolescence, adulthood
Types	Panic disorder, generalized anxiety disorder, phobias, social anxiety disorder, agoraphobia, separation anxiety
Causes	Genetic, environmental, neurobiological
Diagnosis	Clinical evaluation, structured interviews, screening scales
Treatment	Psychotherapy, pharmacotherapy, neuromodulation

Contents

Anxiety disorders are a group of mental health conditions characterized by persistent and excessive fear and worry that impair daily functioning. They manifest across the lifespan and are treated within settings ranging from primary care clinics to specialized centers such as Mayo Clinic and Maudsley Hospital. Major clinical approaches derive from research institutions including National Institute of Mental Health, Johns Hopkins Hospital, University of Oxford, and Harvard Medical School.

Overview

Anxiety presentations are observed in patients seen at Beth Israel Deaconess Medical Center, Kaiser Permanente, Cleveland Clinic, Massachusetts General Hospital, and community clinics affiliated with World Health Organization initiatives. Diagnostic frameworks in manuals published by American Psychiatric Association and international classifications from World Health Organization guide practice. Key historical figures who advanced understanding include clinicians at Sigmund Freud's contemporaneous schools, researchers associated with Ivan Pavlov's laboratory, and later neuroscientists at National Institutes of Health.

Contemporary nosology follows criteria in publications by American Psychiatric Association and coding used by World Health Organization's systems. Common categories include panic disorder (studied at Yale School of Medicine), generalized anxiety disorder (GAD) with trials at Stanford University School of Medicine, social anxiety disorder researched at University College London, specific phobias explored at McGill University Health Centre, agoraphobia evaluated in cohorts from Karolinska Institute, and separation anxiety considered in pediatric clinics at Children's Hospital of Philadelphia. Subtypes and specifiers are addressed in guideline committees at National Institute for Health and Care Excellence and specialty societies like the American Psychological Association.

Etiology research spans genetics labs at Broad Institute, epidemiologic cohorts such as those from Framingham Heart Study contributors, twin registries at Danish Twin Registry, and neuroimaging centers including Massachusetts General Hospital Martinos Center and Functional Magnetic Resonance Imaging Laboratory at University of California, Los Angeles. Risk factors identified in landmark studies from Harvard T.H. Chan School of Public Health and Columbia University include family history seen in registries like Swedish National Patient Register, early-life adversity documented by researchers at University of Toronto, and stressful life events cataloged in projects affiliated with University of Cambridge. Biological mechanisms implicate amygdala circuits studied by teams at Salk Institute, neurotransmitter systems targeted by pharmacology groups at Eli Lilly and Company and Pfizer, and stress-response pathways examined at Rockefeller University.

Assessment protocols derive from structured interviews such as the SCID developed by researchers linked to Columbia University and screening scales validated in multicenter studies involving World Health Organization's collaborations. Primary care screening initiatives have been piloted in systems like Veterans Health Administration, NHS England clinics, and Mount Sinai Health System. Diagnostic imaging and biomarkers are areas of investigation at National Institute of Mental Health and translational centers including Scripps Research.

Evidence-based psychotherapies—cognitive behavioral therapy popularized through work at University of Pennsylvania and exposure therapies advanced by teams at University of Oxford—are first-line options in many guidelines from National Institute for Health and Care Excellence and American Psychiatric Association. Pharmacologic treatments such as selective serotonin reuptake inhibitors were developed by pharmaceutical research at GlaxoSmithKline and Eli Lilly and Company; benzodiazepines trace to synthesis work by chemists associated with Hoffmann-La Roche. Combined care models are implemented in integrated systems like Kaiser Permanente and trialed at academic centers including Yale University. Neuromodulation and novel agents are being tested in clinical trials at Mayo Clinic, Massachusetts General Hospital, and biotech firms such as Cambridge Biomedical.

Large-scale epidemiologic findings have been reported by collaborations among World Health Organization, Global Burden of Disease Study teams, and national surveys like the National Comorbidity Survey and initiatives at Centers for Disease Control and Prevention. Prevalence estimates vary across populations studied by institutions such as University of Melbourne, University of São Paulo, University of Cape Town, and Peking University. Economic and social burden analyses have been conducted by think tanks linked to OECD, European Commission, and public health departments in municipalities like New York City and London.

Historical conceptual shifts are documented in archives at British Library, collections at Wellcome Trust, and writings preserved at Library of Congress. Foundational experiments by Ivan Pavlov, psychoanalytic contributions from circles around Sigmund Freud, and behaviorist work from researchers at University of Chicago informed early models. Contemporary research priorities set by funders including National Institutes of Health, European Research Council, Wellcome Trust, and private foundations at Brain & Behavior Research Foundation focus on precision psychiatry, digital therapeutics developed with companies like Pear Therapeutics, and cross-national trials coordinated by consortia including Global Mental Health partnerships.

Category:Mental health disorders